ALBANY, New York, April 18, 2017: A new research study has recently been added by MarketResearchReports.biz to its comprehensive collection of research reports. The 367-page research study, titled “PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2024,” offers a detailed overview of the market, presenting insights into the key factors that are likely to supplement the growth of the market in the coming years. In addition, the competitive landscape of the global multiple sclerosis and the key segmentation have been offered in the scope of the research study to offer a strong understanding of the market.

The emergence of the novel DMT products is one of the major factors anticipated to encourage the growth of the global multiple sclerosis market in the next few years. The growing demand for improved efficiency and the drugs focusing on clinical unmet needs are expected to accelerate the development of the market in the near future. On the other hand, the rising popularity of biosimilar and generic products are predicted to hamper the growth of the global multiple sclerosis market in the coming few years.

The presence of a strong drugs pipeline and the rising focus on research and development activities are estimated to generate promising opportunities in the forecast period. Furthermore, the introduction of the reimbursement policies is anticipated to accelerate the overall development of the market in the near future. The rising awareness among patients regarding the availability of drugs and therapeutics is predicted to generate promising opportunities in the forecast period. The research study has provided the market share and expected growth rate of the global multiple sclerosis market.

Among the key segments, North America, in the last few years, held a key share of the global multiple sclerosis market. A substantial contribution from the U.S. and the rising incidence of multiple sclerosis are anticipated to supplement the growth of the North America market in the coming years. On the other hand, Asia Pacific is likely to offer promising growth opportunities for the leading players operating in the market. The increasing number of collaborations is anticipated to fuel the growth of the market in the forecast period.

The global market for multiple sclerosis is expected to grow at a healthy pace in the forecast period. A significant rise in the number of players and technological advancements are predicted to enhance the competitive scenario of the overall market in the coming few years. Some of the key players operating in the multiple sclerosis market across the globe are Sanofi (Genzyme), Biogen, Novartis, Merck Serono (EMD Serono), Teva, Bayer, and Roche. Detailed profiles of the leading players, focusing on the financial overview, business strategies, and SWOT reports have been discussed at length in the scope of the research study.